Skip to content

Debt-to-assets at other companies

Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Pfizer logo
PfizerPFE
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
0.3×+0.2×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
0.0×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
0.0×

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4.04B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Calculated from Viking Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's debt-to-assets?
Viking Therapeutics (VKTX) reported debt-to-assets of 0× in Q4 2025.
How has Viking Therapeutics's debt-to-assets changed year-over-year?
Viking Therapeutics's debt-to-assets decreased by 83.3% year-over-year, from 0× to 0×.
What is the long-term trend for Viking Therapeutics's debt-to-assets?
Over 5 years (2020 to 2025), Viking Therapeutics's debt-to-assets has grown at a -32.2% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.